https://doi.org/10.4081/reumatismo.2008.41

Anti-TNFα agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients

Vol. 60 No. 1 (2008)
Abstract Views: 1126
PDF: 757
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Filippini
office@pagepress.org
C. Bazzani
S. Zingarelli
T. Ziglioli
M. Nuzzo
M. Vianelli
C. Biasini Rebaioli
R. Cattaneo
R. Gorla
Objective: To evaluate the efficacy and the safety of anti-TNF-alfa treatment in elderly patients (≥65 years old) with active rheumatoid arthritis (RA), in comparison with younger (17-65 years old). Methods: We considered retrospectively 295 patients, affected by RA and treated with anti-TNF-alfa drugs. They were divided in two groups, according to their age, and followed up for two years: over-65-years old patients (190) and under-65-years old patients (105). Effectiveness of drugs was assessed analyzing RA disease activity (DAS28, DAS44, SDAI), functional status (HAQ) and serological parameters (CRP) before and after anti-TNF-alfa therapy. Safety was studied considering discontinuation rate of biological disease-modifying antirheumatic drugs, and collateral events rate. Results: At baseline, elderly patients showed higher disease activity’s score (DAS 28, DAS44, SDAI, HAQ) with important loss of articular function (worse quality of life, HAQ) than younger patients (p<0.05). During the therapy, improvement in clinical parameters was observed (DAS28, DAS44 and SDAI) with no significant difference between the two groups. In elderly patients disability index, on the contrary, improved less than in younger (p<0.05). After treatment, also CRP decreased less in elderly patients (p<0.05). During the follow-up, 74 over-65-years old patients (38.95%) and 116 under-65-years old patients (38.05%) discontinued anti-TNF-alfa therapy because of loss of efficacy (20.52% vs 11.42%), severe adverse events (17.34% vs 25.67%), voluntary discontinuation or good clinical response (1% vs 0.95%). No differences were shown about the frequency and reasons of anti-TNF-alfa withdrawl (p>0.05). Conclusions: Anti-TNF-alfa treatment was efficacious and safe in both groups of patients. These drugs induced improvement in disease activity, apart from the age. No functional improvement was observed in HAQ, showing the irreversible loss of articular function and the incomplete recovery in elderly patients. Age doesn’t interfere with the possibility to treat elderly patients with anti-TNF-alfa drugs.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Filippini, M., Bazzani, C., Zingarelli, S., Ziglioli, T., Nuzzo, M., Vianelli, M., … Gorla, R. (2008). Anti-TNFα agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients. Reumatismo, 60(1), 41–49. https://doi.org/10.4081/reumatismo.2008.41

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.